Skip to search formSkip to main contentSkip to account menu

KP 1461

Known as: KP-1461, KP1461 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Nucleosides

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
Safety, tolerability, and efficacy of KP-1461 as monotherapy for 124 days in antiretroviral-experienced, HIV type 1-infected subjects.
Treatment of HIV infection with conventional antiretroviral therapy (ART) is a lifelong challenge with significant long-term… 
Highly Cited
2011
Highly Cited
2011
Mutation of HIV-1 Genomes in a Clinical Population Treated with the Mutagenic Nucleoside KP1461
The deoxycytidine analog KP1212, and its prodrug KP1461, are prototypes of a new class of antiretroviral drugs designed to… 
Review
2011
Review
2011
Safety, Tolerability, and Pharmacokinetics of KP-1461 in Phase I Clinical Studies
Background: KP-1461 is a prodrug to KP-1212. KP-1212 is a viral mutagen designed to increase viral error rate. Methods: We… 
2010
2010
KP-1461: a novel anti-HIV drug in limbo?
The path of an experimental drug from the laboratory to U.S. Food and Drug Administration (FDA) approval is typically long, rocky… 
2007
2007
New kind of antiretroviral, KP-1461; clinical trial recruiting. Interview with Stephen Becker, M.D.
KP-1461, an experimental HIV drug already in a phase II trial, works so differently from other antiretrovirals that at first… 
2007
2007
Safety and tolerability of KP-1461 in Phase 1, dose ranging studies in highly antiretroviral experienced HIV infected persons
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)